Clubhouse Media Group, Inc. - Quarter Report: 2013 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2013
o
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
|
For the transition period from ______________ to _____________
Commission file number: 333-140645
(Exact name of registrant as specified in its charter)
Nevada
|
99-0364697
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
No. 5 Beiji Road
Nanning, Guangxi, People’s Republic of China
|
530011
|
|
(Address of principal executive offices)
|
(Zip Code)
|
011-86-771-2020000
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
|
Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
o
|
Accelerated filer
|
o
|
Non-accelerated filer
|
o
|
Smaller reporting company
|
x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
1
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes o No o
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:
As of May 14, 2013, there are 15,812,191 shares of $0.001 par value common stock issued and outstanding.
2
FORM 10-Q
TONGJI HEALTHCARE GROUP, INC.
INDEX
Page
|
|||
PART I.
|
Financial Information
|
4
|
|
Item 1. Financial Statements (Unaudited).
|
4
|
||
Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2013 and December 31, 2012.
|
5
|
||
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2013 and 2012 (Unaudited).
|
6
|
||
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012 (Unaudited).
|
7
|
||
Notes to Condensed Consolidated Financial Statements as of March 31, 2013 and 2012 (Unaudited).
|
8
|
||
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
23
|
||
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
|
29
|
||
Item 4. Controls and Procedures.
|
29
|
||
PART II.
|
Other Information
|
32
|
|
Item 1. Legal Proceedings.
|
32
|
||
Item 1A. Risk Factors.
|
32
|
||
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
|
32
|
||
Item 3. Defaults Upon Senior Securities.
|
32
|
||
Item 4. Mine Safety Disclosures.
|
32
|
||
Item 5. Other Information.
|
32
|
||
Item 6. Exhibits.
|
33
|
3
The unaudited condensed consolidated financial statements of registrant as of March 31, 2013 and December 31, 2012 and for the three months ended March 31, 2013 and 2012 follow. The condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.
4
TONGJI HEALTHCARE GROUP, INC.
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS
|
||||||||
(UNAUDITED)
|
||||||||
March 31, 2013
|
December 31, 2012
|
|||||||
ASSETS
|
||||||||
Current Assets
|
||||||||
Cash and cash equivalents
|
$ | 44,328 | $ | 81,135 | ||||
Accounts receivable, net
|
397,221 | 448,923 | ||||||
Due from related parties
|
55,777 | 107,710 | ||||||
Medicine supplies
|
123,310 | 108,399 | ||||||
Prepaid expenses and other current assets
|
193,680 | 180,424 | ||||||
Total Current Assets
|
814,316 | 926,591 | ||||||
Equipment, net
|
2,019,866 | 2,033,536 | ||||||
Construction in Progress
|
11,371,253 | 11,200,724 | ||||||
TOTAL ASSETS
|
$ | 14,205,435 | $ | 14,160,851 | ||||
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
Current Liabilities
|
||||||||
Accounts payable and accrued expenses
|
$ | 388,615 | $ | 327,324 | ||||
Due to related parties
|
12,103,334 | 11,762,403 | ||||||
Other payables
|
547,108 | 752,637 | ||||||
Current portion of capital lease payable
|
359,503 | 349,050 | ||||||
Total Current Liabilities
|
13,398,560 | 13,191,414 | ||||||
Capital lease payable
|
967,114 | 1,056,415 | ||||||
Contingent liability
|
1,139,264 | 1,121,692 | ||||||
Total Liabilities
|
15,504,938 | 15,369,521 | ||||||
STOCKHOLDERS' DEFICIT
|
||||||||
Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding
|
||||||||
Common stocks; $0.001 par value, 100,000,000 shares authorized and 15,812,191 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively
|
15,812 | 15,812 | ||||||
Additional paid in capital
|
435,629 | 434,377 | ||||||
Accumulated deficit
|
(1,875,524 | ) | (1,785,336 | ) | ||||
Accumulated other comprehensive income
|
124,580 | 126,477 | ||||||
Total Stockholders' Deficit
|
(1,299,503 | ) | (1,208,670 | ) | ||||
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
|
$ | 14,205,435 | $ | 14,160,851 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
5
TONGJI HEALTHCARE GROUP, INC.
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
||||||||
FOR THE THREE MONTH PERIODS ENDED MARCH 31,
|
||||||||
(UNAUDITED) | ||||||||
2013
|
2012
|
|||||||
OPERATING REVENUE
|
||||||||
In-patient service revenue
|
$ | 250,055 | $ | 349,255 | ||||
Out-patient service revenue
|
235,522 | 286,236 | ||||||
Total operating revenue
|
485,577 | 635,491 | ||||||
OPERATING EXPENSES
|
||||||||
Salary and fringes
|
154,767 | 182,938 | ||||||
Medicine and supplies
|
234,456 | 328,411 | ||||||
Other operating expenses
|
92,359 | 46,049 | ||||||
Administrative expenses
|
33,480 | 42,638 | ||||||
Depreciation expense
|
23,184 | 110,142 | ||||||
Total operating expenses
|
538,246 | 710,178 | ||||||
LOSS FROM OPERATIONS
|
(52,669 | ) | (74,687 | ) | ||||
OTHER INCOME (EXPENSE)
|
||||||||
Other income
|
7,380 | 12,103 | ||||||
Interest expense, net of income
|
(44,899 | ) | (41,170 | ) | ||||
Total Other Expense
|
(37,519 | ) | (29,067 | ) | ||||
LOSS BEFORE INCOME TAXES
|
(90,188 | ) | (103,754 | ) | ||||
Provision for income taxes
|
0 | 0 | ||||||
NET LOSS
|
(90,188 | ) | (103,754 | ) | ||||
Foreign currency translation loss
|
(1,897 | ) | (2,690 | ) | ||||
NET COMPREHENSIVE LOSS
|
$ | (92,085 | ) | $ | (106,444 | ) | ||
Net loss per common stock-Basis and Diluted
|
$ | (0.006 | ) | $ | (0.007 | ) | ||
Weighted average common stock outstanding
|
||||||||
Basic and Diluted
|
15,812,191 | 15,812,191 | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
6
TONJI HEALTHCARE GROUP, INC.
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||
FOR THE THREE MONTH PERIODS ENDED MARCH 31,
|
||||||||
(UNAUDITED)
|
||||||||
2013
|
2012
|
|||||||
Cash flows from operating activities:
|
||||||||
Net Loss
|
$ | (90,188 | ) | $ | (103,754 | ) | ||
Adjustments to reconcile net loss to
|
||||||||
net cash provided by (used in) operating activities:
|
||||||||
Depreciation expense
|
23,184 | 110,142 | ||||||
Stock option expense
|
1,252 | 1,279 | ||||||
Increase/(decrease) in assets and liabilities:
|
||||||||
Accounts receivable
|
53,571 | 34,489 | ||||||
Medicine supplies
|
(14,427 | ) | (12,326 | ) | ||||
Prepaid expenses and other current assets
|
(12,465 | ) | 788 | |||||
Accounts payable and accrued expenses
|
59,813 | 54,218 | ||||||
Other payables
|
(208,526 | ) | (383 | ) | ||||
Contingent liability
|
14,054 | - | ||||||
Total adjustment
|
(83,544 | ) | 188,207 | |||||
Net Cash Provided by (Used in) Operating Activities
|
(173,732 | ) | 84,453 | |||||
Cash flows from investing activities:
|
||||||||
Acquisitions of fixed assets
|
(790 | ) | (9,510 | ) | ||||
Construction in Progress
|
(122,187 | ) | (747,044 | ) | ||||
Due from related parties
|
52,335 | (165 | ) | |||||
Net Cash Used in Investing Activities
|
(70,642 | ) | (756,719 | ) | ||||
Cash flows from financing activities:
|
||||||||
Payments of capital lease
|
(84,797 | ) | (75,977 | ) | ||||
Due to related parties
|
289,975 | 741,291 | ||||||
Net Cash Provided by Financing Activities
|
205,178 | 665,314 | ||||||
Effects of foreign currency translation
|
2,389 | 264 | ||||||
Net decrease in Cash and Cash Equivalents
|
(36,807 | ) | (6,688 | ) | ||||
Cash and Cash Equivalents-Beginning of Period
|
81,135 | 32,126 | ||||||
Cash and Cash Equivalents-Ending of Period
|
$ | 44,328 | $ | 25,438 | ||||
Cash Paid During the Year for:
|
||||||||
Income taxes
|
$ | - | $ | - | ||||
Interest paid
|
$ | 33,491 | $ | 42,952 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
|
7
March 31, 2013 and 2012
(UNAUDITED)
NOTE 1- ORGANIZATION
Nanning Tongji Hospital, Inc. ("NTH") was established in Nanning in the province of Guangxi of the People’s Republic of China ("PRC") by the Nanning Tongji Medical Co. Ltd. and an individual on October 30, 2003.
NTH is a designated hospital for medical insurance in the city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.
On December 19, 2006, NTH filed Articles of Incorporation in the State of Nevada to establish Tongji Healthcare Group, Inc. (the "Company"). On the same day, Tongji, Inc., a wholly owned subsidiary of the Company, was incorporated in the State of Colorado. Tongji Inc. was dissolved on March 25, 2011.
On December 27, 2006, Tongji acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger, pursuant to which NTH became a wholly owned subsidiary of Tongji. The Company was authorized to issue 50,000,000 shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share. The Company issued 15,652,557 shares of common stock to the stockholders of NTH in exchange for 100% of the issued and outstanding shares of common stock of NTH. Thereafter and for purposes of these consolidated financial statements the "Company" and "NTH" are used to refer to the operations of Nanning Tongji Hospital Co. Ltd. The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the stockholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH, with NTH being treated as the continuing operating entity.
According to the PRC Regulation of Healthcare Institutions, hospitals are subject to registration with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising.
NTH must register with and maintain an operating license from the local health department, due to the fact that NTH currently maintains a facility with over 100 beds. NTH is subject to review by the local health department at least once every three years. If NTH fails to meet their standards, NTH’s business license may be revoked. NTH is also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. NTH dedicates a very small percentage of its resources to providing free public services.
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements include all of the adjustments, which, in the opinion of management, are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet information as of December 31, 2012 was derived from the audited consolidated financial statements included in the Form 10-K. These condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended on December 31, 2012 (“Form 10-K”), filed with the Commission on April 1, 2013.
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the condensed consolidated financial statements and the Form 10-K.
BASIS OF PRESENTATION AND CONSOLIDATION
These financial statements present the Company’s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include Tongji Healthcare, Inc. and its wholly-owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”.
CASH AND CASH EQUIVALENTS
For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company’s cash is held in bank accounts in the People’s Republic of China (“PRC” or China) and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $44,328 as of March 31, 2013. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.
USE OF ESTIMATES
The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
TRANSLATION ADJUSTMENT
The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:
March 31, 2013
|
|
Balance sheet
|
RMB 6.27 to US $1.00
|
Statement of operations and other comprehensive loss
|
RMB 6.28 to US $1.00
|
December 31, 2012
|
|
Balance sheet
|
RMB 6.30 to US $1.00
|
Statement of operations and other comprehensive loss
|
RMB 6.30 to US $1.00
|
March 31, 2012
|
|
Statement of operations and other comprehensive loss
|
RMB 6.30 to US $1.00
|
RECLASSIFICATIONS
Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.
REVENUE RECOGNITION
The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.
The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.
Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.
ACCOUNTS RECEIVABLE
Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.
For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.
10
March 31, 2013 and 2012
(UNAUDITED)
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
The Company has estimated a bad debt allowance of approximately $42,000 as of March 31, 2013 and December 31, 2012.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2013 and December 31, 2012 the fair value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, notes payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.
FAIR VALUE MEASUREMENTS
FASB ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.
Various inputs are considered when determining the fair value of the Company’s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.
|
Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.
|
|
|
Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).
|
|
|
Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).
|
The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.
The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.
CONCENTRATIONS, RISKS, AND UNCERTAINTIES
All of the Company’s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. In addition, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.
11
March 31, 2013 and 2012
(UNAUDITED)
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
INVENTORIES
Inventories consisting of medicine supplies, both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of inventories with the market value and allowance is made for writing down their inventories to market value, if such value is lower.
EQUIPMENT
Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.
CONSTRUCTION-IN-PROGRESS
A hospital facility currently under development is accounted for as construction-in-progress. Construction-in-progress is recorded at acquisition cost, including land rights cost, development expenditure, and professional fees capitalized during the course of construction for the purpose of financing the project. Upon completion of the project, the cost of construction-in-progress will be transferred to fixed assets, at which time depreciation will commence.
CAPITALIZATION OF INTEREST
Interest cost is capitalized for qualifying assets when the portion of the interest cost incurred during the assets' acquisition periods could have been avoided if expenditures for the assets had not been made. The amount capitalized in an accounting period is determined by applying the capitalization rate to the average amount of accumulated expenditures for the asset during the period. The capitalization rates used in an accounting period is based on the rates applicable to borrowings outstanding during the period (also see Note 4).
Capitalization period covers the duration of the activities required to get the asset ready for its intended use, provided that expenditures for the asset have been made and interest cost is being incurred. Interest capitalization continues as long as those activities and the incurrence of interest cost continue.
IMPAIRMENT OF LONG-LIVED ASSETS
The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.
The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the periods ended March 31, 2013 and 2012.
12
March 31, 2013 and 2012
(UNAUDITED)
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
BASIC AND DILUTED EARNINGS PER SHARE
Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, “Earnings Per Share.” Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the period ended March 31, 2013. During the three months period ended March 31, 2013, the average market price of the common stock during the year was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.
INCOME TAXES
FASB ASC Topic 740, "Income Taxes” requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
In accordance with ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB ASC Topic 740” , which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.
The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.
In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.
13
March 31, 2013 and 2012
(UNAUDITED)
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
The Company had accrued approximately $40,000 for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.
STATEMENT OF CASH FLOWS
In accordance with FASB ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.
EMPLOYEE BENEFIT COSTS
The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company’s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees’ salaries above a fixed threshold amount; employees contribute 8% and the Company’s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.
STOCK-BASED COMPENSATION
For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, “Equity” and FASB ASC Topic 718, “Compensation — Stock Compensation,” we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.
Stock-based compensation costs that have been included in operating expenses amounted to $1,252 and $1,279, for the three month periods ended March 31, 2013 and 2012, respectively.
COMPREHENSIVE INCOME
The Company reports comprehensive income in accordance with FASB ASC Topic 220 “Comprehensive Income," which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.
Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $92,085 and $106,444 for the three months periods ended March 31, 2013 and 2012, respectively.
While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (“AOCI”) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $124,580 and $126,477 as of March 31, 2013 and December 31, 2012, respectively.
14
March 31, 2013 and 2012
(UNAUDITED)
NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
RECENT ACCOUNTING PRONOUNCEMENTS
In December 2011, the FASB issued ASU 2011-11 Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities: The amendments in this Update will enhance disclosures required by U.S. GAAP by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. This information will enable users of an entity’s financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position, including the effect or potential effect of rights of setoff associated with certain financial instruments and derivative instruments in the scope of this Update. An entity is required to apply the amendments for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. It does not have a material impact on the Company’s condensed consolidated financial statements.
In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, which allows an entity to first assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset, other than goodwill, is impaired. If an entity concludes, based on an evaluation of all relevant qualitative factors, that it is not more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, it will not be required to perform a quantitative impairment test for that asset. Entities are required to test indefinite-lived assets for impairment at least annually and more frequently if indicators of impairment exist. The adoption of this ASU does not have a significant effect on our results of operations or financial position.
Other recently issued accounting pronouncements did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.
GOING CONCERN
The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $12,584,244, an accumulated deficit of $1,875,524, and a stockholders’ deficit of $1,299,503 as of March 31, 2013. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.
Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.
15
March 31, 2013 and 2012
(UNAUDITED)
Equipment as of March 31, 2013 and December 31, 2012 comprised the following:
Estimated Useful Lives (Years)
|
March 31,
2013
|
December 31,
2012
|
||||||||||
Office equipment
|
5-10
|
$
|
85,859
|
$
|
85,491
|
|||||||
Medical equipment
|
5
|
3,118,251
|
3,104,102
|
|||||||||
Fixtures
|
10
|
112,929
|
112,445
|
|||||||||
Vehicles
|
5
|
44,380
|
44,190
|
|||||||||
Total equipment
|
3,361,419
|
3,346,228
|
||||||||||
Less accumulated depreciation
|
(1,341,553
|
)
|
(1,312,692
|
)
|
||||||||
Equipment, net
|
$
|
2,019,866
|
$
|
2,033,536
|
The Company purchased and started depreciating certain medical equipments at the beginning of 2012. Those equipments are to be placed in service upon receiving usage approval from the Chinese government and hiring qualified personnel. As of March 31, 2013, the Company still has not received the approval. On September 30, 2012, the company adjusted depreciation expenses and stopped depreciating on those medical equipments. The Company has been working with Nanning Municipal Health Bureau to obtain the approval to place the equipments in service and making great efforts to recruit qualified personnel. The Company expects to be able to place the assets in service in April 2013. If the Company is unsuccessful in being able to place the assets in service we will assess the need to record an impairment charge for the assets. Therefore, depreciation expense charged to operations was $23,184 and $110,142 for the three month periods ended March 31, 2013 and 2012, respectively.
NOTE 4- CONSTRUCTION IN PROGRESS
The Company is constructing a new hospital building on leased land. Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. The Company is required to make payments for construction costs of approximately $7,587,300 and any excess construction cost payments incurred during the construction phase. As of March 31, 2013, the Company had paid approximately $11,370,000 for the construction of the hospital building. In addition to what it had paid for the hospital construction, the Company estimates the additional costs to complete the project to be $2,200,000. The land lease term will start upon completion of the new hospital building. The new hospital building is expected to be completed at the end of 2013.
The Company will amortize the cost of the hospital building over the life of the land lease of twenty years. Capitalized interest was approximately $248,000 as of March 31, 2013.
16
March 31, 2013 and 2012
(UNAUDITED)
NOTE 5- CONTINGENCIES
Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
On August 3, 2011, Guangxi Jingjian Real Estate Development Company (“Jingjian”) filed a civil suit against Nanning Tongji Hospital, Inc. (“Nanning Tongji”), a subsidiary of the Company, in the People’s Court in Qingxiu District, Nanning City, People’s Republic of China (“People’s Court”). In its complaint, Jingjian asserts a breach of contract claim against Nanning Tongji, alleging that Nanning Tongji has failed to make timely and total payment of the project transfer fee under certain Business Building Project Agreement between Nanning Tongji and Jingjian. Jingjian seeks a total of RMB 3,162,500 (approximately $498,000) in the complaint, including payment of the remaining RMB 800,000 (approximately $126,000) project transfer fee and liquidated damages of RMB 2,362,500 (approximately $372,000) for late payment of such fee. On February 1, 2012, the People’s Court ruled that Nanning Tongji shall pay approximately $176,000 to Jingjian, including the remaining project transfer fee and a late fee of such payment. On August 14, 2012, Jingjian appealed the decision to the Intermediate People’s Court in Nanning City, People’s Republic of China (“Intermediate Court”), disputing the calculation of the damages of the People’s Court. On September 09, 2012, the Intermediate Court affirmed the decision of the People’s Court. On March 1, 2013, Nanning Tongji borrowed fund from a related party and paid RMB 1,096,922 (approximately $174,000) to Jianjing pursuant to the final judgment.
In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against Nanning Tongji in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against Nanting Tongji, alleging that Nanning Tongji had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among Nanning Tongji, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu Districe, Nanning City (the “Village Committee”). One December 30, 2009, the People’s Court ruled that Nanning Tongji shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, Nanning Tongji appealed to the Intermediate Court, alleging, among other things, that Nanning Tongji was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. Pending a court decision, the Company had accrued approximately $1,140,000 as of March 31, 2013.
NOTE 6- MAJOR SUPPLIERS AND CUSTOMERS
The Company purchases the majority of its medicine supplies from Guangxi Tongji Medicine Co. Ltd., a related party with common major stockholders. Medicine purchased accounted for 48% and 66% of all medicine purchases for three month period ended March 31, 2013 and 2012. Amounts due were approximately $975,000 and $900,000 as of March 31, 2013 and 2012.
17
March 31, 2013 and 2012
(UNAUDITED)
NOTE 6- MAJOR SUPPLIERS AND CUSTOMERS - continued
The Company had three major customers for the three month period ended March 31, 2013 and two major customers for three month period ending March 31, 2012: Nanning Social Insurance Center, Guangxi Province Social Insurance Center, and China UMS Co., Ltd. Nanning Social Insurance Center accounted for 37% and 42% of revenue for the three month periods ended March 31, 2013 and 2012. Guangxi Province Social Insurance Center accounted for 7% and 14% of revenue for the three month periods ended March 31, 2013 and 2012. China UMS Co., Ltd. accounted for 9% and 0% of revenue for the three month periods ended March 31, 2013 and 2012.
As of March 31, 2013 and December 31, 2012, accounts receivable due from Nanning Social Insurance Center, Guangxi Province Social Insurance Center, and China UMS Co., Ltd. was approximately $440,000, and $413,000 respectively.
NOTE 7- CAPITAL LEASE OBLIGATIONS
Sale and Lease Back
On March 25, 2011, the Company completed a financing arrangement with an independent third party to sell and leaseback certain machinery and equipment. The net carrying value of the machinery and equipment sold was $262,683. The machinery and equipment was sold for $371,517, of which $334,365 was received in cash and $37,152 was held as refundable deposit. The transaction has been accounted for as a financing arrangement, wherein the property remains on the Company’s books and will continue to be depreciated. A financing obligation in the amount of $371,517, representing the proceeds, has been recorded under “Capital Lease Payable” in the Company’s Balance Sheet, and is being reduced based on payments under the lease. Capital lease payable was $263,099 as of March 31, 2013. The lease does not contain an option to renew. There is also no contingent rent or concessions, or any leasehold improvement incentives.
The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:
Year Ending December 31
|
Amount
|
|||
2013
|
$
|
75,582
|
||
2014
|
100,776
|
|||
2015
|
100,776
|
|||
2016
|
33,592
|
|||
Total minimum lease payments
|
310,727
|
|||
Less: interest payments
|
47,628
|
|||
PV of minimum capital lease payments
|
263,099
|
|||
Less: current obligations under capital lease
|
75,870
|
|||
Long term capital lease obligation
|
$
|
187,229
|
In October 2011, the Company entered into an agreement to lease certain machinery and equipment that are classified as capital leases. The cost of equipment under capital leases of approximately $1,450,000 is included in the Balance Sheet equipment at March 31, 2013. Accumulated depreciation of the leased equipment at March 31, 2013 was approximately $311,000. Depreciation of assets under capital leases is included in depreciation expense. Capital lease payable was $1,314,418 as of March 31, 2013.
NOTE 7- CAPITAL LEASE OBLIGATIONS - continued
The lease has a term of 5 years and requires minimum annual rental payments including principal and interest as follows:
Year Ending December 31
|
Amount
|
|||
2013
|
$
|
280,718
|
||
2014
|
376,596
|
|||
2015
|
376,596
|
|||
2016
|
219,681
|
|||
Total minimum lease payments
|
1,253,591
|
|||
Less: interest payments
|
190,073
|
|||
PV of minimum capital lease payments
|
1,063,518
|
|||
Less: current obligations under capital lease
|
283,633
|
|||
Long term capital lease obligation
|
779,885
|
Other payables as of March 31, 2013 and December 31, 2012 consists of the following:
March 31, 2013
|
December 31, 2012
|
|||||||
Advance from customers
|
$
|
2,733
|
$
|
(4,778)
|
||||
Welfare payable
|
39,711
|
47,310
|
||||||
Capital lease deposits paid by third party
|
355,944
|
354,409
|
||||||
Lawsuit settlement payable
|
-
|
177,024
|
||||||
Other payables
|
148,720
|
178,672
|
||||||
Total
|
$
|
547,108
|
$
|
752,637
|
NOTE 9- STOCKHOLDERS' EQUITY
Preferred Stock
As of March 31, 2013 and December 31, 2012, the Company has 20,000,000 shares of preferred stock authorized with a par value of $0.001. There are no shares issued and outstanding as of March 31, 2013.
Common Stock
As of March 31, 2013 and December 31, 2012, the Company has 100,000,000 shares of common stock authorized with a par value of $0.001.
Statutory Reserves
As stipulated by the Company Law of the PRC, net income after taxation can only be distributed as dividends after appropriation has been made for the following:
i.
|
Making up cumulative prior years’ losses, if any;
|
ii.
|
Allocations to the “Statutory surplus reserve” of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company’s registered capital;
|
iii.
|
Allocations to the discretionary surplus reserve, if approved in the stockholders’ general meeting.
|
As of March 31, 2013, the Company had accumulated deficits of $1,875,524. Therefore, the Company did not appropriate a reserve for the statutory surplus reserve for the three months period ended March 31, 2013.
Stock Option
Stock-based compensation amounted to $1,252 and $1,279 for the three month periods ended March 31, 2013 and 2012.
On March 3, 2011, an option to purchase 100,000 shares of common stock was granted to the company’s CFO. The option vests in two equal installments of 33,333 shares each, with the last installment being 33,334 shares, starting on the first anniversary of grant and subsequent anniversaries thereafter, at an exercise price equivalent to the closing price per share of common stock on the date of grant.
The fair value of the option award is estimated on the date of grant using the Black Scholes model to be $15,400. The valuation was based on the assumptions noted in the following table.
105
|
%
|
|||
Expected dividends
|
0
|
%
|
||
Stock price
|
0.24
|
|||
Expected term (in years)
|
3 years
|
|||
Risk-free rate
|
1.32
|
%
|
NOTE 9- STOCKHOLDERS' EQUITY - continued
The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the option at the time of grant. The dividend yield on our common stock is assumed to be zero since we do not pay dividends and have no current plans to pay them in the future. The market price volatility of our common stock was based on historical volatility since May 13, 2010. The expected life of the options is based upon our anticipated expectations of exercise behavior since no options have been exercised in the past to provide relevant historical data.
The fair value of the option granted will be expensed according to following schedule:
The following table summarizes stock option activity in the Company's stock-based compensation plans for the three month period ended March 31, 2013.
Number of
Shares
|
Weighted
Average
Exercise
Price
|
Aggregate
Intrinsic Value
(in thousands)
|
Number of
Shares
Exercisable
|
|||||||||||||
Outstanding at January 1, 2013
|
100,000
|
$
|
0.24
|
$
|
-
|
-
|
||||||||||
Granted
|
-
|
-
|
-
|
-
|
||||||||||||
Exercised
|
-
|
-
|
-
|
-
|
||||||||||||
Cancelled/expired
|
-
|
-
|
-
|
-
|
||||||||||||
Outstanding at March 31, 2013
|
100,000
|
$
|
0.24
|
$
|
-
|
-
|
There were no options granted, exercised or cancelled/expired during the three month period ended March 31, 2013.
NOTE 11- RELATED PARTY TRANSACTIONS AND COMMITMENTS
Due from/to Related Parties
The Company has entered into agreements with Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Switch Factory whereby the Company from time to time will advance amounts to assist them in their operations. The three companies have common major stockholders. The advanced amounts accrue interest at a rate of 1.5% per annum. The amount receivable as of March 31, 2013 and December 31, 2012 was $55,777 and $107,710, respectively. Interest income for the three month periods ended March 31, 2013 and 2012 was approximately $165 and $165, respectively.
The Company has entered into an agreement with the Chairman and a stockholder of the Company, Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Tongji Electric Coating Factory, whereby the Company from time to time will be advanced amounts to assist them in their operations. The advanced amounts accrue interest at a rate of 1.5% per annum. As of March 31, 2013 and December 31, 2012, $12,103,334 and $11,762,403 were payable to these related parties respectively. Interest expense for the three month periods ended March 31, 2013 and 2012 was $36,699 and $34,445 respectively.
Rental Commitments
The Company entered into a lease agreement for their hospital with Guangxi Tongji Medicine Co. Ltd that expires December 2014. The monthly lease payment is approximately $2,500. The Company also in the process of cooperating with Guangxi Construction Engineering Corporation Langdong 8th Group in building a new 600-bed hospital in Nanning, China. It expects the new hospital to be completed by the end of 2013. The hospital is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group and, when completed, the land will be leased by the Company for a twenty-year term. The annual lease payments will gradually increase each year. Based on the exchange rate at March 31, 2013, minimum future lease payments are as follows:
Related Party
|
Non-Related Party
|
Total
|
||||||||||
1-5 years
|
$
|
47,162
|
$
|
1,858,832
|
$
|
1,905,994
|
||||||
6-10 years
|
-
|
2,829,091
|
2,829,091
|
|||||||||
11-15 years
|
-
|
3,227,555
|
3,227,555
|
|||||||||
16-20 years
|
-
|
3,578,203
|
3,578,203
|
|||||||||
Total
|
$
|
47,162
|
$
|
11,493,681
|
$
|
11,540,843
|
22
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related condensed notes included elsewhere in this report. Our financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements.
Overview
Nanning Tongji Hospital, Inc. ("NTH" or “Tongji Hospital”) was established in Nanning city Guangxi province of the Peoples’ Republic of China ("PRC") by the Guangxi Tongji Medical Co. Ltd. and an individual on October 30, 2003.
NTH is a designated hospital for medical insurance in Nanning city and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.
On December 27, 2006, we, through our wholly-owned subsidiary, Tongji, Inc., a Colorado company, acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger –unless otherwise provided, all references to “the Company”, “us”, “we” refer to Tongji Healthcare Group, Inc. and its subsidiaries, Tongji, Inc. and NTH. We issued 15,652,557 shares of common stock to the shareholders of NTH in exchange for 100% of the issued and outstanding shares of NTH. Accordingly, NTH became a wholly owned subsidiary of Tongji, Inc. We have been in the business of operating hospitals and providing healthcare services in Nanning, Guangxi province of the PRC.
The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the shareholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH. We treated NTH as the continuing operating entity.
According to the PRC Regulation of Healthcare Institutions, hospitals are required to register with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising.
We must register with and maintain an operating license from the local health department due to the fact that we currently maintain a facility with over 100 beds. We are subject to review by the local health department at least once every three years. If we fail to meet their standards, our business license may be revoked. We are also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. We dedicate a very small percentage of our resources to providing public services.
We have two sources of operating revenues: in-patient service revenues and out-patient service revenues. In addition to providing services to our patients, we also sell pharmaceutical drugs to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon the rates established by the local government. Revenues are recorded at estimated net amounts due from patients or third-party payers. Revenues from pharmaceutical drug sales are recognized upon the drug being administered to a patient or at the time a prescription by a registered physician is filled.
23
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). Historically, there have been no significant differences between the amounts the Company billed the government Medicare funds and the amounts collected from the Medicare funds.
We had three major customers for the three month period ended March 31, 2013 and two major customers for the three month period ended March 31, 2012. Nanning Social Insurance Center accounted for 37% and 42% of revenue for the three month periods ended March 31, 2013 and 2012. Guangxi Province Social Insurance Center accounted for 7% and 14% of revenue for the three month periods ended March 31, 2013 and 2012. China UMS Co., Ltd. accounted for 9% and 0% of revenue for the three month periods ended March 31, 2013 and 2012.
About 48% of the drugs and medications we use in the hospital and sell to our patients are purchased from Guangxi Tongji Medicine Co., Ltd., a related company controlled by our Chief Executive Officer, Yunhui Yu, at prevailing market prices. The rest comes from other suppliers. One of these other suppliers is responsible for more than 10% of our total purchases.
Difference in the Medical System between the U.S. and China
In the United States, most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients also receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid and insurance companies.
For financial reporting purposes, hospitals in the United States record revenues based upon established billing rates less adjustment for contractual allowances. Revenues are recorded based upon the amounts due from the patients and third-party payers, including federal and state (under the Medicare and Medicaid programs) managed care health plans, health insurance companies, and employers. Estimates of contractual allowances under third-party payer arrangements are based upon the payment terms specified in the related contractual agreements. Third-party payer contractual payment terms are generally based upon predetermined rates per diagnosis, per diem rates, or discounted fee-for-service rates.
Due to the complexities involved in determining amounts ultimately due under reimbursement arrangements with a large number of third-party payers, which are often subject to interpretation, the reimbursement actually received by U.S. hospitals for health care services is sometimes different from their estimates.
The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid by cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to based upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by these Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who pay cash.
Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies, we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the amounts we receive for services provided to Medicare patients.
24
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
Results of Operation - Three months ended March 31, 2013
Material changes of items in our Statement of Operations for the three months ended March 31, 2013, as compared to the three months ended March 31, 2012, are discussed below.
Operating Revenue – Operating revenue for the three month period ended March 31, 2013, which resulted primarily from in-patient service revenue and out-patient revenue, was $485,577, a decrease of $149,914 or 24%, as compared with the operating revenue of $635,491 for the same period of 2012. Our out-patient service revenue was $235,522 for the three month period ended March 31, 2013, as compared to $286,236 for the same period in 2012, a decrease of $50,714 or 18%. The decrease was primarily the result of a decrease in average daily out-patient service revenue per patient. Our in-patient service revenue was $250,055 for the three month period ended March 31, 2013 as compared to $349,255, a decrease of $99,200 or 28% as compared to the same period in 2012. The decrease in the in-patient service revenue was primarily due to a change in the Municipal Health Insurance regulations. Starting at the end of 2012, Municipal Health Insurance requires that the hospitals stop waiving co-insurance payments from patients. This has discouraged patients from using our in-patient services and greatly impacted the admission headcount in the in-patient service sector.
Operating Expenses – Operating expenses were $538,246 for the three month period ended March 31, 2013, a decrease of $171,932 or 24% as compared to $710,178 for the same period of 2012. The decrease was primarily due to a decrease of approximately of $94,000 in medicine and supplies sales resulting from the decrease of in-patient services and a decrease of approximately of $87,000 in depreciation expenses, offset by an increase of approximately $46,310 in other operating expense.
Loss from Operations - Operating loss was $52,669 for the three month period ended March 31, 2013, a decrease of $22,018 or 29% as compared to an operating loss of $74,687 for the same period of 2012. The primary reasons for the decrease are the aforementioned changes in operating revenue and operating expenses.
Interest Expense – Interest expense for the three-month period ended March 31, 2013 was $44,899 as compared to $41,170 for the three-month period ended March 31, 2012, an increase of $3,729 or 9%. The increase was primarily due to the increase in loans from related parties and capital lease obligations.
Net Loss - As a result of the forgoing, the Company had a net loss of $90,188 during the quarter ended March 31, 2013, compared to a net loss of $103,754 for the comparative period in 2012, a decrease of $13,566 or 13%.
Trends, Events and Uncertainties
The China Ministry of Health, as well as other related agencies, has proposed changes to the price limit we can charge for medical services, drugs and medications. We cannot predict the impact of these proposed changes since the changes are not fully defined and we do not know whether those proposed changes will be implemented or when they may take effect.
We are in the process of building a new 600-bed hospital building in Nanning city on leased land. We expect the new hospital building to be completed by the end of 2013. The hospital building is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group (“Langdong 8th Group”). The lease payments for the land will start after the construction is completed. Annual lease payments will increase every year. Our agreement with Langdong 8th Group obligates us to pay approximately $7,870,000 for construction related costs. In addition, we are responsible for any additional costs necessary to complete the project. As of March 31, 2013, we had paid approximately $11,370,000 for the construction of the hospital. We borrowed most of the funds from our related company Guangxi Tongji Medicine Co., Ltd. In addition to what we had paid for the hospital building construction, we estimate the additional costs to complete the project to be $2,200,000. We will continue to operate in our existing hospital buildings after the completion of the new hospital building.
25
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
We plan to acquire other hospitals and companies involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for these acquisitions and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements. We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or businesses in the healthcare industry.
Other than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations. Our business is not seasonal in nature.
Accounting Estimates
In the United States most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients also receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid and insurance companies.
For financial reporting purposes, hospitals in the United States record revenues based upon established billing rates less adjustment for contractual allowances. Revenues are recorded based upon the amounts due from the patients and third-party payers, including federal and state agencies (under the Medicare and Medicaid programs) managed care health plans, health insurance companies, and employers. Estimates of contractual allowances under third-party payer arrangements are based upon the payment terms specified in the related contractual agreements. Third-party payer contractual payment terms are generally based upon predetermined rates per diagnosis, per diem rates, or discounted fee-for-service rates.
Due to the complexities involved in determining amounts ultimately due under reimbursement arrangements with a large number of third-party payers, which are often subject to interpretation, the reimbursement actually received by U.S. hospitals for health care services is sometimes different from their estimates.
The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid for in cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to based upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by theses Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who only use cash.
Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the
26
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
Liquidity and Capital Resources
We generally finance our operations through our operating profits and borrowings from related parties. As of the date of this report, we have not experienced any difficulty in raising funds from related parties, and we have not experienced any liquidity problems in settling our payables in our ordinary course of business. We believe that we have adequate funds and capital with respect to conducting its business over the next twelve months.
The following shows our material sources and (uses) of cash during the three month periods ended March 31, 2013 and 2012:
2013
|
2012
|
|||||||
Cash provided by (used in) operating activities
|
$
|
(173,732)
|
$
|
84,453
|
||||
Cash (used in) investing activities
|
$
|
(70,642)
|
$
|
(756,719)
|
||||
Cash provided by financing activities
|
$
|
205,178
|
$
|
665,314
|
The Company carefully monitors and controls the amount of cash used to fund operating activities. However, substantial funds are required to fund the construction costs on the new hospital building and a lawsuit settlement (see note 5). Financing of operations has come primarily from advances from related parties. We are dependent on related parties to provide working capital and pay our management team until such time as our operations are profitable. There can be no assurances that related parties will continue to provide additional capital. Without additional capital, we may be forced to cease operations and liquidate.
Operating Activities
Net cash used in operating activities primarily consists of net loss, as adjusted by depreciation, stock option, and changes in operating assets and liabilities such as accounts receivable, medical supplies, capital lease deposits, prepaid expense and other current assets, accounts payables and accrued liabilities , and other payables.
Net cash used in operating activities was $173,732 for the three months ended March 31, 2013, an increase of $258,185 or 305.72%, as compared with the net cash provided by operating activities of $84,453 for the same period in 2012. The increase in net cash used in operating activities was primarily due to a lawsuit settlement payout of approximately $174,000 for the three month period ended March 31, 2013.
Investing Activities
Net cash used in investing activities primarily consists of acquisition of equipment and purchases of construction in progress.
Net cash used in investing activities was $70,642 for the three months ended March 31, 2013, a decrease of $686,077 or 90.66%, as compared with the net cash used in investing activities of $756,719 for the same period in 2012. The decrease in net cash used in investing activities was primarily due to a decrease of approximately $625,000 in construction in progress because the construction progress of the new hospital building is close to the final stage.
Financing Activities
Net cash provided by financing activities primarily consists of proceeds from related party loans.
27
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
Net cash provided by financing activities was $205,178 for the three months ended March 31, 2013, a decrease of $460,136 or 69.16%, as compared with the net cash provided by financing activities of $665,314 for the same period in 2012. The decrease was primarily attributable to less funding needs because the construction progress of the new hospital building is close to the final stage.
Working Capital
Working capital is current liabilities deducted from current assets.
Our working capital was negative $12,584,244 for the three months ended March 31, 2013, as compared with negative $12,264,823 for the year ended December 31, 2012, which is primarily attributable to additional financial assistance of approximately $340,000 from related parties to fund the construction of the new hospital and the lawsuit settlement.
Rental Commitments
The Company has entered into a lease agreement for their hospital building with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. The monthly lease payment is approximately $2,500. The Company is also in the process of cooperating with Langdong 8th Group in building a new 600-bed hospital building in Nanning, China. Management expects the new hospital building to be completed by the end of 2013. The hospital building is being constructed by Langdong 8th Group and the land will be leased by the Company for a twenty-year term starting from the date the building is completed. The annual lease payments will gradually increase each year. Based on the exchange rate at March 31, 2013, minimum future lease payments are as follows:
Related Party
|
Non-Related Party
|
Total
|
||||||||||
1-5 years
|
$
|
47,162
|
$
|
1,858,832
|
$
|
1,905,994
|
||||||
6-10 years
|
-
|
2,829,091
|
2,829,091
|
|||||||||
11-15 years
|
-
|
3,227,555
|
3,227,555
|
|||||||||
16-20 years
|
-
|
3,578,203
|
3,578,203
|
|||||||||
Total
|
$
|
47,162
|
$
|
11,493,681
|
$
|
11,540,843
|
Going Concern
The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $12,584,244, an accumulated deficit of $1,875,524, and a stockholders’ deficit of $1,299,503 as of March 31, 2013. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.
28
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued
Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) plan to convert existed related parties’ loans into equity, 2) to complete construction of the new hospital and begin generating revenue by the end of the next year, 3) plan to increase sales revenue with additional medical equipments. No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet items reasonably likely to have a material effect on our financial condition.
Not applicable.
Evaluation of Disclosure Controls
Our management maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As of March 31, 2012, our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2012 as a result of the material weaknesses identified in our internal control over financial reporting. These material weaknesses are discussed in “Management’s Report on Internal Control over Financial Reporting” below. Our management considers our internal control over financial reporting to be an integral part of our disclosure controls and procedures.
Management’s Report on Internal Control over Financial Reporting
The Company’s management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. The Company’s management is also required to assess and report on the effectiveness of the Company’s internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of the Company’s financial reporting for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that: (i) pertain to maintaining records that in reasonable detail accurately and fairly reflect the Company’s transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of the Company’s financial statements and that receipts and expenditures of company assets are made in accordance with management authorization; and (iii) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.
29
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.
As of March 31, 2013, our management, under the supervision of and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as required by Rules 13a-15(c) and 15d-15(c) under the Exchange Act. In making this assessment, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework , including the following five framework components: i) control environment, ii) risk assessment, iii) control activities, iv) information and communications, and v) monitoring.
Our management evaluated the design and operating effectiveness of our internal control over financial reporting as part of this assessment, using its knowledge and understanding of our organization, operations, and processes, to determine, in its judgment, the sources and potential likelihood of misstatements in financial reporting. Based on this assessment, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that our internal control over financial reporting was not effective as of March 31, 2013.
Specifically, our management identified certain matters involving internal control and our operations that it considered to be material weaknesses. As defined in the Exchange Act, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant's annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified by our management as of March 31, 2013, are described below:
We did not design, implement, or maintain effective entity-level controls related to our control environment, resulting in the following significant control deficiencies:
|
||
o
|
The Code of Business Conduct and Ethics, which was specifically designed for public company applicability, has yet to be formally acknowledged by members of management and the finance department.
|
o
|
There is an absence of independence and financial expertise on the Board of Directors, and we do not have an Audit Committee or a formalized internal audit function, limiting its ability to provide effective oversight of our management.
|
Our management believes that the pervasive nature of these control deficiencies, when aggregated, impact all significant accounts and disclosures and rise to the level of material weakness.
The full implementation of, and related training for, our newly-formalized IT policies and procedures were still in process at year-end. Accordingly, we lacked sufficiently-trained personnel to provide for adequate segregation of duties within the accounting system and effective oversight of controls over access, change, data, and security management. Because this control deficiency, and the related segregation of duties constraints, is pervasive in nature and impacts all significant accounts, our management believes this deficiency rises to the level of material weakness.
|
30
Item 4. Controls and Procedures - continued
2013 Planned Remediation
As financial conditions permit, we plan to take the following actions to improve our internal control over financial reporting.
●
|
Require all members of our management and the finance department across all corporate entities to certify receipt of the revised Code of Business Conduct and Ethics by signature. Signed copies will be retained by our management. Thereafter, our management plans to periodically require signatories to acknowledge that they understand the contents of the Code of Business Conduct and Ethics, and whether they are aware of anyone in our Company that might have violated some part of the Code.
|
●
|
Recruit an independent financial expert to the Board of Directors to chair an Audit Committee and formalize roles and responsibilities over our internal control over financial reporting for the Board and our management. Our management also plans to develop and implement a formal corporate internal audit capability, reporting directly to an independent Audit Committee, to provide effective oversight of our internal control over financial reporting.
|
●
|
Continue to engage the services of qualified consultants with China GAAP, U.S. GAAP and SEC reporting experience to support our financial reporting and SOX compliance requirements, including assistance with the following:
|
o
|
Remediating identified material weaknesses;
|
o
|
Monitoring our internal control over financial reporting on an ongoing basis;
|
|
o
|
Managing our period-end financial closing and reporting processes; and
|
o
|
Identifying and resolving non-routine or complex accounting matters.
|
Complete the implementation of, and related training for, its IT policies and procedures related to access, change, data, and security management to ensure that all relevant financial information is secure, identified, captured, processed, and reported within the accounting system and spreadsheets supporting financial reporting.
|
●
|
Continue providing training to accounting personnel regarding our significant policies and procedures related to accounting, finance, and internal control to ensure that financial reporting competencies are strengthened.
|
Our management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures, as well as its internal control over financial reporting, on an ongoing basis, and is committed to taking further action and implementing additional improvements, as necessary and as funds allow. However, our management cannot guarantee that the measures taken or any future measures will remediate the material weaknesses identified or that any additional material weaknesses or significant deficiencies will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting.
Notwithstanding the material weaknesses described above, our management believes that there are no material inaccuracies or omissions of material fact and, to the best of its knowledge, believes that the consolidated financial statements included in this annual report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.
Changes in Internal Control over Financial Reporting
No changes in the Company's internal control over financial reporting has come to management's attention during the Company's last fiscal quarter that have materially affected, or are likely to materially affect, the Company's internal control over financial reporting.
31
Item 4. Controls and Procedures - continued
Limitations on Controls
Management does not expect that the Company's disclosure controls and procedures or the Company's internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and the Company's chief executive officer and chief financial officer have concluded that the Company's disclosure controls and procedures are effective at that reasonable assurance level.
PART II - OTHER INFORMATION
On August 3, 2011, Guangxi Jingjian Real Estate Development Company (“Jingjian”) filed a civil suit against NTH, in the People’s Court in Qingxiu District, Nanning City, People’s Republic of China (“People’s Court”). In its complaint, Jingjian asserted a breach of contract claim against NTH, alleging that NTH had failed to make timely and total payment of the project transfer fee under certain Business Building Project Agreement between NTH and Jingjian. Jingjian seeks a total of RMB 3,162,500 (approximately $498,000) in the complaint, including payment of the remaining RMB 800,000 (approximately $126,000) project transfer fee and liquidated damages of RMB 2,362,500 (approximately $372,000) for late payment of such fee. On February 1, 2012, the People’s Court ruled that NTH shall pay approximately $176,000 to Jingjian, including the remaining project transfer fee and a late fee for such payment. On August 14, 2012, Jingjian appealed the decision to the Intermediate People’s Court in Nanning City, People’s Republic of China (“Intermediate Court”), disputing the calculation of the damages of the People’s Court. On September 09, 2012, the Intermediate Court affirmed the decision of the People’s Court. On March 1, 2013, NTH borrowed fund from a related party and paid RMB 1,096,922 (approximately $174,000) to Jianjing pursuant to the final judgment.
In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against NTH in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against NTH, alleging that NTH had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among NTH, Tingyouyuxiang and Langdong 8th Group. On December 30, 2009, the People’s Court ruled that NTH shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee of approximately $320,000. On March 9, 2012, NTH appealed to the Intermediate Court, alleging, among other things, that NTH was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. Pending a court decision, the Company had accrued approximately $1,140,000 as of March 31, 2013.
Item 1A.
|
Risk Factors.
|
Not Applicable.
None.
None.
Not applicable.
None.
32
Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.
Exhibit No.
|
Title of Document
|
3.1
|
Articles of Incorporation (1)
|
3.2
|
Bylaws (1)
|
10.1
|
Employment Contracts (1)
|
10.2
|
Hospital Lease (1)
|
10.3
|
Agreement with Guangxi Tongji Medicine Co., Ltd. (1)
|
10.4
|
Agreement for Medicare Service - The Management Center of Social Medical Treatment Insurance of Nanning (1)
|
10.5
|
Agreement for Medicare Service - Social Security Department of Guangxi Zhuang Municipality (1)
|
101.INS
|
XBRL Instance Document (3)
|
101.SCH
|
XBRL Taxonomy Extension Schema Document (3)
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document (3)
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document (3)
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document (3)
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document (3)
|
(1) Incorporated by reference to the same exhibit filed with our registration statement on Form SB-2 (File No. 333-140645).
(2) The Exhibit attached to this Form 10-Q shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
(3) Attached as Exhibits 101 to this report are the following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) related notes to these financial statements tagged as blocks of text. The XBRL-related information in Exhibits 101 to this Quarterly Report on Form 10-Q shall not be deemed “filed” or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and is not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of those sections.
33
Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
TONGJI HEALTHCARE GROUP, INC.
|
||
Date: May 15, 2013
|
By:
|
/s/ Yunhui Yu
|
Yunhui Yu
President and Chief Executive Officer
(Principal Executive Officer)
|
Date: May 15, 2013
|
By:
|
/s/ Eric Zhang
|
Eric Zhang
Chief Financial Officer
(Principal Financial Officer)
|
34